The results of immunohistochemical analysis showed that compared with the stage I lung cancer group, the expression levels of COPG2IT1 and HLA.DQA1 in the stage III lung cancer group were significantly increased, and the expression levels of LYN, C3 and TNFRSF17 were significantly decreased (Figure 7). This evidence concerns the gene COPG2IT1 and lung cancer.